Showing results (301-310 of 407) with videos related to

Sort By:
Pageof 41
Expert Opinion on Investigational Drugs|May 26, 2023
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I studyKyung-Sang Yu, Byungwook Kim, Dongseong Shin, et al.
Annals of the Rheumatic Diseases|May 8, 2012
After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?Richard J Wakefield, Maria Antonietta D'Agostino, Esperanza Naredo, et al.
RMD Open|October 19, 2022
A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseasesKastriot Kastrati, Daniel Aletaha, Gerd R Burmester, et al.
Modern Rheumatology|April 2, 2022
Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 yearsNaoki Ishiguro, Yoshiya Tanaka, Tsukasa Matsubara, et al.
Annals of the Rheumatic Diseases|October 31, 2019
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019Kevin L Winthrop, Michael E Weinblatt, Joan Bathon, et al.
Modern Rheumatology|December 15, 2021
Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3)Tatsuya Atsumi, Yoshiya Tanaka, Tsukasa Matsubara, et al.
Postgraduate Medical Journal|July 24, 2012
After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?Richard J Wakefield, Maria Antonietta D'Agostino, Esperanza Naredo, et al.
Annals of the Rheumatic Diseases|November 13, 2012
Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statementMonika M Schoels, Désirée van der Heijde, Ferdinand C Breedveld, et al.
Annals of the Rheumatic Diseases|March 4, 2022
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritisPhilip J Mease, Atul A Deodhar, Désirée van der Heijde, et al.
Rheumatology (Oxford, England)|November 3, 2021
Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trialFrank Behrens, Philipp Sewerin, Eugenio de Miguel, et al.
Pageof 41